Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting more than 21 million people worldwide. It is a systemic autoimmune disease that affects people of all ages and can have a major impact on quality of life. It is characterized by chronic inflammation (mainly of the joints), pain and fatigue. In 30–40 percent of cases, conventional drugs are ineffective or poorly tolerated. Now, our biopharmaceuticals are paving the way for a new treatment that can impede progression of the disease and prevent joint damage and pain.